文献速递白血病

英国六十年急性髓系白血病试验研究:试验设计的过去、现在与未来

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
PubMed 文献 · Br J Haematol · 2019-12-12

自1959年首项急性髓系白血病(AML)试验以来,英国医学研究理事会及后续国家癌症研究所连续六十年开展随机试验。六十年间AML诊断、特征描述与治疗发生转变,临床试验法规也发生巨变,结局持续改善。诊断精细化带来定制治疗与疾病监测,有望进一步改善结局,但复杂性要求试验设计方法演变。本文审视首批AML试验的指导原则在当今的相关性及下一代试验方法学家面临的挑战。

要点

  • 英国连续六十年开展AML随机试验,见证了诊断、治疗与法规的巨变及结局持续改善。
  • 诊断精细化促进定制治疗与疾病监测,有望进一步改善结局但增加试验设计复杂性。
  • 首批AML试验的指导原则在当今仍具相关性,试验设计方法需随复杂性演变。

核心结论

  • 首批AML试验的指导原则在当今仍具相关性,但诊断与治疗复杂性要求试验设计方法演变。

研究设计与样本

  • 本文为综述性文章,回顾英国医学研究理事会及国家癌症研究所自1959年以来连续六十年的AML随机试验历程。

主要发现

  • 六十年间AML诊断、特征描述与治疗发生转变,临床试验法规发生巨变,结局持续改善。
  • 诊断精细化带来定制治疗与疾病监测,有望进一步改善结局但增加试验设计复杂性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the launch of their first trial in Acute myeloid leukaemia (AML) in 1959, the Medical Research Council (and latterly National Cancer Research Institute) has conducted randomised trials in AML uninterrupted for six decades. These sixty years have seen a transformation in the way we diagnose, characterise and treat the disease, (and indeed a sea change in clinical trial regulations) and a continuing improvement in outcomes. The increasing refinement of diagnosis, leading to the advent of tailored therapies, and the use of disease monitoring both have the potential to improve outcomes further, but the associated complexities will require an evolution in our approach to trial design. This article looks at the extent to which the guiding principles of the first AML trials remain relevant today, and the challenges facing the next generation of trials methodologists.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hills RK. Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future. Br J Haematol. 2019. PMID: 31833053. doi:10.1111/bjh.16357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。